This article does not . cite any sources (December 2015)
Perazine ( Taxilan) is a moderate-potency typical antipsychotic of the phenothiazine class. It is quite similar to chlorpromazine, and acts as a dopamine antagonist. A 2014 systematic review compared it with other antipsychotic drugs:
Perazine versus other antipsychotic drugs for schizophrenia
The number, size and reporting of
randomized controlled perazine trials are insufficient to present firm conclusions about the properties of this antipsychotic. It is possible that perazine is associated with a similar risk of extrapyramidal side effects as some atypical antipsychotics but this is based on few comparisons of limited power. 
Findings in words
Findings in numbers
Quality of evidence
No better or deterioration
Follow-up: average 5 weeks Perazine may decrease the chance of experiencing this outcome. These findings are based on data of low quality.
RR 0.43 (0.23 to 0.81)
Less than 30% BPRS reduction
Follow-up: mean 5 weeks The average overall mental state score in the perazine group was lower than for those given other antipsychotic drugs but the difference between the groups was not clear. These findings are based on data of low quality.
RR 0.82 (0.61 to 1.09)
Needing antiparkinson medication
Follow-up: average 5 weeks Perazine might increase the risk of experiencing this outcome but at present it is not possible to be confident about the difference between perazine and other antipsychotic drugs. Data supporting this finding are very limited.
RR 4.5 (1.04 to 19.45)
Leaving the study early - due to adverse events
Follow-up: average 4 weeks There was not a clear difference between perazine and the other antipsychotic drugs for this general outcome reflecting overall adverse event 'load'. These findings are based on data of low quality.
0.87 (0.4 to 1.9)
Acceptability of treatment
Leaving the studies early - any reason
Follow-up: 5 weeks Perazine and the comparison antipsychotic drugs were equally tolerated. These findings are based on data of low quality.
RR 0.62 (0.35 to 1.1)
No study reported any data on outcomes such as
quality of life or information relating to satisfaction with care.
See also [ edit ]
External links [ edit ]